Stein Steven H — SEC insider filings
SEC reporting owner CIK 1673776. 45 insider filings on record with FilingPulse; latest filed 2026-11-18.
Transaction summary — filings shown
Covers all 45 filings on record, filed 2020-11-18 to 2026-11-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 20 legs across 15 filings — 418,102 shares, $43,728,857 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 97.
- Largest priced transaction: sale of 73,969 shares @ $119.12 ($8,811,010) in INCYTE CORP, filed 2026-11-10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| INCYTE CORP (INCY) | CMO & Head of Late-Stage Dev. | 39 | — | 20 legs · 418,102 sh · $43,728,857 | 90 |
| Theseus Pharmaceuticals, Inc. (THRX) | Director | 3 | — | — | 4 |
| Kura Oncology, Inc. (KURA) | Director | 2 | — | — | 2 |
| Repare Therapeutics Inc. (RPTX) | Director | 1 | — | — | 1 |
Insider filings — Stein Steven H
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | INCYTE CORP (INCY) | Option exercise (M): 576 @ $68.25 · Sale (S): 576 @ $121.98 · Option exercise (M): 576 (derivative) @ $0 | EDGAR |
| 2026-11-10 | 4 | INCYTE CORP (INCY) | Option exercise (M): 8,539 @ $68.62 · Option exercise (M): 12,335 @ $72.27 · Option exercise (M): 16,428 @ $80.50 · Option exercise (M): 15,054 @ $74.78 · Option exercise (M): 23,526 @ $77.67 · Option exercise (M): 18,331 @ $61.76 · +31 more | EDGAR |
| 2026-07-20 | 4 | INCYTE CORP (INCY) | Sale (S): 1,877 @ $114.73 · Grant/award (A): 9,798 @ $0 · Grant/award (A): 24,496 (derivative) @ $0 · Grant/award (A): 42,298 (derivative) @ $0 | EDGAR |
| 2026-07-16 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 21,830 @ $114.88 · Sale (S): 28,237 @ $113.05 · Tax withholding (F): 3,088 @ $115.09 | EDGAR |
| 2026-07-07 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 2,177 @ $116.86 | EDGAR |
| 2026-05-20 | 4/A | INCYTE CORP (INCY) | Grant/award (A): 44,124 @ $0 | EDGAR |
| 2026-04-17 | 4 | INCYTE CORP (INCY) | Grant/award (A): 39,049 @ $0 | EDGAR |
| 2026-01-21 | 4 | INCYTE CORP (INCY) | Grant/award (A): 19,932 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | INCYTE CORP (INCY) | Sale (S): 15,634 @ $101.70 | EDGAR |
| 2026-01-05 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 13,292 @ $98.77 | EDGAR |
| 2025-12-03 | 4 | INCYTE CORP (INCY) | Sale (S): 2,559 @ $102.96 · Tax withholding (F): 17,093 @ $102.04 · Sale (S): 20,105 @ $102.51 | EDGAR |
| 2025-11-07 | 4 | INCYTE CORP (INCY) | Option exercise (M): 1,194 @ $83.83 · Option exercise (M): 2,995 @ $95.76 · Option exercise (M): 1,044 @ $95.76 · Sale (S): 5,233 @ $102.20 · Option exercise (M): 1,194 (derivative) @ $0 · Option exercise (M): 2,995 (derivative) @ $0 · +1 more | EDGAR |
| 2025-07-23 | 4 | INCYTE CORP (INCY) | Sale (S): 3,706 @ $67.94 | EDGAR |
| 2025-07-16 | 4 | INCYTE CORP (INCY) | Sale (S): 14,952 @ $68.47 · Tax withholding (F): 1,555 @ $69.98 · Tax withholding (F): 1,596 @ $68.25 · Grant/award (A): 12,277 @ $0 · Grant/award (A): 30,692 (derivative) @ $0 · Grant/award (A): 27,629 (derivative) @ $0 | EDGAR |
| 2025-07-07 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 12,714 @ $68.17 | EDGAR |
| 2025-04-03 | 4 | INCYTE CORP (INCY) | Grant/award (A): 37,198 @ $0 · Grant/award (A): 20,967 @ $0 | EDGAR |
| 2025-01-22 | 4 | INCYTE CORP (INCY) | Sale (S): 12,352 @ $72.69 · Grant/award (A): 28,202 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 10,692 @ $72.46 | EDGAR |
| 2024-08-14 | 4 | INCYTE CORP (INCY) | Sale (S): 11,608 @ $60.63 | EDGAR |
| 2024-07-17 | 4 | INCYTE CORP (INCY) | Grant/award (A): 13,895 @ $0 · Tax withholding (F): 1,555 @ $64.25 · Grant/award (A): 31,088 (derivative) @ $0 | EDGAR |
| 2024-07-03 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 8,316 @ $59.02 | EDGAR |
| 2024-06-20 | 4 | Repare Therapeutics Inc. (RPTX) | Grant/award (A): 54,000 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | INCYTE CORP (INCY) | Grant/award (A): 7,377 @ $0 | EDGAR |
| 2024-02-14 | 4 | Theseus Pharmaceuticals, Inc. (THRX) | Disposition to issuer (D): 3,250 (derivative) | EDGAR |
| 2024-01-22 | 4 | INCYTE CORP (INCY) | Grant/award (A): 30,580 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | INCYTE CORP (INCY) | Sale (S): 7,365 @ $65.51 | EDGAR |
| 2023-08-03 | 4 | INCYTE CORP (INCY) | Sale (S): 21,511 @ $63.28 | EDGAR |
| 2023-07-18 | 4 | INCYTE CORP (INCY) | Grant/award (A): 13,535 @ $0 · Grant/award (A): 28,385 (derivative) @ $0 | EDGAR |
| 2023-07-06 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 8,442 @ $62.08 | EDGAR |
| 2023-06-13 | 4 | Theseus Pharmaceuticals, Inc. (THRX) | Grant/award (A): 19,500 (derivative) @ $0 · Grant/award (A): 3,250 (derivative) @ $0 | EDGAR |
| 2023-01-24 | 4 | INCYTE CORP (INCY) | Grant/award (A): 4,980 @ $0 · Grant/award (A): 27,096 (derivative) @ $0 | EDGAR |
| 2023-01-06 | 4 | INCYTE CORP (INCY) | Sale (S): 28,399 @ $79.78 | EDGAR |
| 2022-10-19 | 4 | Theseus Pharmaceuticals, Inc. (THRX) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2022-07-06 | 4 | INCYTE CORP (INCY) | Grant/award (A): 18,941 @ $0 · Tax withholding (F): 3,856 @ $79.25 · Grant/award (A): 25,665 (derivative) @ $0 | EDGAR |
| 2022-06-30 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 11,488 @ $75.63 | EDGAR |
| 2022-06-23 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2022-01-21 | 4 | INCYTE CORP (INCY) | Grant/award (A): 15,054 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | INCYTE CORP (INCY) | Grant/award (A): 28,926 @ $0 | EDGAR |
| 2021-11-23 | 4 | INCYTE CORP (INCY) | Grant/award (A): 379 @ $0 · Grant/award (A): 2,355 @ $0 | EDGAR |
| 2021-07-07 | 4 | INCYTE CORP (INCY) | Grant/award (A): 7,853 @ $0 · Tax withholding (F): 2,953 @ $83.58 · Tax withholding (F): 402 @ $83.34 · Grant/award (A): 15,054 (derivative) @ $0 | EDGAR |
| 2021-06-30 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 22,079 @ $85.61 | EDGAR |
| 2021-06-23 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2021-01-27 | 4 | INCYTE CORP (INCY) | Option exercise (M): 3,795 @ $68.62 · Sale (S): 3,795 @ $100 · Option exercise (M): 3,795 (derivative) @ $0 | EDGAR |
| 2021-01-20 | 4 | INCYTE CORP (INCY) | Grant/award (A): 23,044 @ $0 · Grant/award (A): 12,743 (derivative) @ $0 | EDGAR |
| 2020-11-18 | 4 | INCYTE CORP (INCY) | Grant/award (A): 1,232 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-02 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1673776 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs